{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:18:05Z","timestamp":1792786685712,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Bristol-Myers Squibb","id":[{"id":"https:\/\/ror.org\/00gtmwv55","id-type":"ROR","asserted-by":"crossref"}]},{"name":"AstraZeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jdiacomp.2013.05.004","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T21:49:12Z","timestamp":1373406552000},"page":"473-478","source":"Crossref","is-referenced-by-count":171,"title":["Urinary tract infections in patients with diabetes treated with dapagliflozin"],"prefix":"10.1016","volume":"27","author":[{"given":"Kristina M.","family":"Johnsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Ptaszynska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sugg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamik J.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"List","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9733","key":"10.1016\/j.jdiacomp.2013.05.004_bb0005","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.jdiacomp.2013.05.004_bb0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/oxfordjournals.aje.a000181","article-title":"Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women","volume":"161","author":"Boyko","year":"2005","journal-title":"American Journal of Epidemiology"},{"issue":"6","key":"10.1016\/j.jdiacomp.2013.05.004_bb0015","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s11908-002-0042-y","article-title":"Lower genital tract infections in diabetic women","volume":"4","author":"Donders","year":"2002","journal-title":"Current Infectious Disease Reports"},{"issue":"10","key":"10.1016\/j.jdiacomp.2013.05.004_bb0020","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.jdiacomp.2013.05.004_bb0025","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.ijantimicag.2007.07.042","article-title":"Urinary tract infections in patients with diabetes mellitus: epidemiology, pathogenesis and treatment","volume":"31","author":"Geerlings","year":"2008","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"6","key":"10.1016\/j.jdiacomp.2013.05.004_bb0030","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1099\/00222615-48-6-535","article-title":"Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals","volume":"48","author":"Geerlings","year":"1999","journal-title":"Journal of Medical Microbiology"},{"issue":"12","key":"10.1016\/j.jdiacomp.2013.05.004_bb0035","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2337\/diacare.23.12.1737","article-title":"Risk factors for symptomatic urinary tract infection in women with diabetes","volume":"23","author":"Geerlings","year":"2000","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jdiacomp.2013.05.004_bb0040","doi-asserted-by":"crossref","first-page":"744","DOI":"10.2337\/diacare.23.6.744","article-title":"Asymptomatic bacteriuria may be considered a complication in women with diabetes","volume":"23","author":"Geerlings","year":"2000","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.jdiacomp.2013.05.004_bb0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/0091270011400604","article-title":"SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus","volume":"52","author":"Ghosh","year":"2012","journal-title":"The Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1016\/j.jdiacomp.2013.05.004_bb0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1053\/jinf.2000.0723","article-title":"Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status","volume":"41","author":"Goswami","year":"2000","journal-title":"The Journal of Infection"},{"issue":"6","key":"10.1016\/j.jdiacomp.2013.05.004_bb0055","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"issue":"Suppl","key":"10.1016\/j.jdiacomp.2013.05.004_bb0060","first-page":"235","article-title":"Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus","volume":"22","author":"Hoepelman","year":"2003","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"5","key":"10.1016\/j.jdiacomp.2013.05.004_bb0065","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","article-title":"Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"Journal of Diabetes and its Complications"},{"issue":"25","key":"10.1016\/j.jdiacomp.2013.05.004_bb0070","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJM199912163412507","article-title":"Infections in patients with diabetes mellitus","volume":"341","author":"Joshi","year":"1999","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.jdiacomp.2013.05.004_bb0075","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1016\/j.jdiacomp.2013.05.004_bb0080","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jdiacomp.2013.05.004_bb0085","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","article-title":"Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"51","author":"Meng","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.jdiacomp.2013.05.004_bb0090","article-title":"Characterization of urinary tract infections in the setting of pharmacologically-induced glucosuria","author":"Parikh","year":"2011"},{"key":"10.1016\/j.jdiacomp.2013.05.004_bb0095","unstructured":"Rackley, R. (2011). Neurogenic bladder. Medscape, Available at: http:\/\/emedicine.medscape.com\/article\/453539-overview. Accessed December 11, 2011."},{"issue":"12","key":"10.1016\/j.jdiacomp.2013.05.004_bb0100","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.jdiacomp.2013.05.004_bb0105","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0002-9343(82)90511-3","article-title":"Infection and diabetes: the case for glucose control","volume":"72","author":"Rayfield","year":"1982","journal-title":"American Journal of Medicine"},{"issue":"7","key":"10.1016\/j.jdiacomp.2013.05.004_bb0110","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.jdiacomp.2013.05.004_bb0115","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2174\/138920011796504509","article-title":"Kidney in diabetes: from organ damage target to therapeutic target","volume":"12","author":"Salvatore","year":"2011","journal-title":"Current Drug Metabolism"},{"issue":"6","key":"10.1016\/j.jdiacomp.2013.05.004_bb0120","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0924-8579(02)00114-0","article-title":"Urinary tract infection in patients with neurogenic bladder dysfunction","volume":"19","author":"Sauerwein","year":"2002","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"10","key":"10.1016\/j.jdiacomp.2013.05.004_bb0125","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, double-blind, placebo-controlled trial","volume":"13","author":"Strojek","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"9","key":"10.1016\/j.jdiacomp.2013.05.004_bb0130","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jdiacomp.2013.05.004_bb0135","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Annals of Internal Medicine"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872713001128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872713001128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T13:53:28Z","timestamp":1588946008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872713001128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1056872713001128"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2013.05.004","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}